Taihua plc, an investment holding company, manufactures and sells pharmaceutical products in the People’s Republic of China. The company operates through four segments: Paclitaxel, Homoharringtonine, Traditional Chinese Medicines (TCM) Products, and Forsythia. It develops, manufactures, and distributes active pharmaceutical ingredients, which comprise paclitaxel that is extracted from yew tree for the treatment of ovaries, breast, lungs, skin, and mucous membranes cancer; and Homoharringtonine, an alkaloid extracted from cephalotaxus tree for the treatment of acute myeloid leukaemia and other cancers. The company also develops, produces, distributes, and sells TCM products, including Gengnianan tablets for the treatment of symptoms of menopause; Duzhong Pingya tablets for use in the treatment of high blood pressure; Zaoren Anshen Keli for the treatment of insomnia and headaches caused by neurological problems; and Bunao Anshen tablets for the treatment of headaches, insomnia, and palpitation. Its TCM products also consist of Jiangzi Jianfei tablets for cholesterol and help weight loss; Dabaidu capsules for the treatment of urinary infection; Runing tablets for the treatment of pain of sore breasts; and Bian Tong Pian for the treatment of constipation. In addition, Taihua plc is involved in the cultivation, harvest, and sale of Forsythia, a flowering shrub for use as raw material in TCM preparations. The company was formerly known as China Natural Plc and changed its name to Taihua plc in September 2006. Taihua plc was incorporated in 2006 and is based in Xi'an, the People’s Republic of China.
taihua plc (TAIH:London Stock Exchange)
No. 16 Zhong Hua
Room 201, Unit 3
239 KeJi Road, Hi-tech Zone
Phone: 86 29 8832 6501
Fax: 86 29 8832 6502www.taihplc.com
|No competitor information is available for TAIH.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact TAIHUA PLC, please visit www.taihplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.